Finance

Lists
Why is EVT up 4,70%?
Dive Deeper
EVT:FRA
Evotec SE
3,08 €
+4,70%
(+0,14) 1D
6 ოქტ, 11:06:04 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for EVT...
Open
2,93 €
High
3,10 €
Low
2,93 €
Mkt. cap
550,45 მლნ.
Avg. vol.
4,51 ათ.
Volume
2,14 ათ.
52-wk high
7,49 €
52-wk low
2,73 €
EPS
-1,11 €
Shares outstanding
148,72 მლნ.
No. of employees
4 ათ.
Open
2,93 €
High
3,10 €
Low
2,93 €
Mkt. cap
550,45 მლნ.
Avg. vol.
4,51 ათ.
Volume
2,14 ათ.
52-wk high
7,49 €
52-wk low
2,73 €
EPS
-1,11 €
Shares outstanding
148,72 მლნ.
No. of employees
4 ათ.
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
2 საათის წინ
Evotec loses research chief and Evotec stock gains 2.36 percent
AD HOC NEWS
AD HOC NEWS
·
22 საათის წინ
Evotec loses research chief. Evotec stock gains 2.05 percent
AD HOC NEWS
AD HOC NEWS
·
23 საათის წინ
Evotec stock reports weaker 2026 guidance ahead of results
Profile
Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology. Wikipedia
About Evotec SE
CEO-
Employees4,46 ათ.
Founded1993
Headquarters-
SectorHealth care
Websiteevotec.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
163,89 მლნ.
253,27 მლნ.
156,64 მლნ.
143,48 მლნ.
Cost of goods sold
163,95 მლნ.
174,81 მლნ.
158,21 მლნ.
145,06 მლნ.
Cost of revenue
163,95 მლნ.
174,81 მლნ.
158,21 მლნ.
145,06 მლნ.
Research and development expenses
8,71 მლნ.
9,83 მლნ.
10,08 მლნ.
10,26 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42,31 მლნ.
44,35 მლნ.
43,79 მლნ.
39,29 მლნ.
Operating expense
43,53 მლნ.
55,25 მლნ.
44,85 მლნ.
87,74 მლნ.
Total operating expenses
207,48 მლნ.
230,06 მლნ.
203,07 მლნ.
232,80 მლნ.
Operating income
-43,59 მლნ.
23,21 მლნ.
-46,42 მლნ.
-89,32 მლნ.
Other non operating income
1,19 მლნ.
-33,96 მლნ.
1,89 მლნ.
-839,00 ათ.
EBT including unusual items
-42,96 მლნ.
29,46 მლნ.
-122,18 მლნ.
-48,12 მლნ.
EBT excluding unusual items
-43,36 მლნ.
18,35 მლნ.
-47,40 მლნ.
-94,00 მლნ.
Income tax expense
127,00 ათ.
14,84 მლნ.
-244,00 ათ.
-1,47 მლნ.
Effective tax rate
-0,30%
50,37%
0,20%
3,06%
Other operating expenses
-7,50 მლნ.
1,07 მლნ.
-9,02 მლნ.
38,20 მლნ.
Net income
-43,09 მლნ.
14,62 მლნ.
-121,94 მლნ.
-46,65 მლნ.
Net profit margin
-26,29%
5,77%
-77,84%
-32,51%
Earnings per share
-0,24
-
-
-
Interest and investment income
841,00 ათ.
11,84 მლნ.
-
-
Interest expense
-2,28 მლნ.
-
-2,58 მლნ.
-2,97 მლნ.
Net interest expenses
-1,44 მლნ.
11,84 მლნ.
-2,58 მლნ.
-2,97 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,27 მლნ.
41,91 მლნ.
-22,60 მლნ.
-64,88 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები